Bioconversion of C20- and C22-polyunsaturated fatty acids into 9S,15S- and 11S,17S-dihydroxy fatty acids by Escherichia coli expressing double-oxygenating 9S-lipoxygenase from Sphingopyxis macrogoltabida.

Double-oxygenating lipoxygenase (LOX) converted C20- and C22-polyunsaturated fatty acids (PUFAs) into C20 dihydroxy fatty acids (DiHFAs) as inflammatory mediators and C22 DiHFAs as specialized pro-resolving mediators, which are involved in the resolution of inflammation and infection in humans, and their isomers, respectively. However, the quantitative bioconversion of C20- and C22-PUFAs into 9S,15S- and 11S,17S-DiHFAs has been not attempted to date, respectively. Here, we performed the efficient quantitative production of 9S,15S- and 11S,17S-DiHFAs by Escherichia coli expressing 9S-LOX from Sphingopyxis macrogoltabida. The optimal bioconversion conditions of the C20 PUFA arachidonic acid or the C22-PUFA docosahexaenoic acid were pH 8.5, 35 °C, 6 mM substrate, and 5 g dry cells/L for C20 PUFAs or 7 g dry cells/L for C22-PUFAs, respectively. Under these conditions, E. coli expressing double-oxygenating 9S-LOX from S. macrogoltabida converted arachidonic acid, eicosapentaenoic acid, docosapentaenoic acidn-3, and docosahexaenoic acid into 5.85 mM 9S,15S-dihydroxyeicosatetraenoic acid, 5.79 mM 9S,15S-dihydroxyeicosapentaenoic acid, 5.89 mM 11S,17S-hydroxydocosapentaenoic acidn-3, and 5.24 mM 11S,17S-dihydroxydocosahexaenoic acid in 40, 30, 50, and 60 min, with conversion yields of 97.5%, 96.5%, 98.1%, and 87.3%; and volumetric productivities of 8.78, 11.6, 7.07, and 5.24 mM/h, respectively. To date, these are the highest concentrations, conversion yields, and volumetric productivities reported in the bioconversion of C20- and C22-PUFAs into DiHFAs.

Autophagy inhibits cancer stemness in triple-negative breast cancer via miR-181a-mediated regulation of ATG5 and/or ATG2B.

Autophagy has a dual role in the maintenance of cancer stem cells (CSCs), but the precise relationship between autophagy and cancer stemness requires further investigation. In this study, it was found that luminal and triple-negative breast cancers require distinct therapeutic approaches because of their different amounts of autophagy flux. We identified that autophagy flux was inhibited in triple-negative breast cancer (TNBC) CSCs. Moreover, miRNA-181a (miR-181a) expression is upregulated in both TNBC CSCs and patient tissues. Autophagy-related 5 (ATG5) and autophagy-related 2B (ATG2B) participate in the early formation of autophagosomes and were revealed as targets of miR-181a. Inhibition of miR-181a expression led to attenuation of TNBC stemness and an increase in autophagy flux. Furthermore, treatment with curcumin led to attenuation of cancer stemness in TNBC CSCs; the expression of ATG5 and ATG2B was enhanced and there was an increase of autophagy flux. These results indicated that ATG5 and ATG2B are involved in the suppression of cancer stemness in TNBC. In summary, autophagy inhibits cancer stemness through the miR-181a-regulated mechanism in TNBC. Promoting tumor-suppressive autophagy using curcumin may be a potential method for the treatment of TNBC.

Regioselectivity of an arachidonate 9S-lipoxygenase from Sphingopyxis macrogoltabida that biosynthesizes 9S,15S- and 11S,17S-dihydroxy fatty acids from C20 and C22 polyunsaturated fatty acids.

Lipoxygenases (LOXs) biosynthesize lipid mediators (LMs) as human signaling molecules. Among LMs, specialized pro-resolving mediators (SPMs) are involved in the resolution of inflammation and infection in humans. Here, the putative LOX from the bacterium Sphingopyxis macrogoltabida was identified as arachidonate 9S-LOX. The enzyme catalyzed oxygenation at the n-12 position of C20 and C22 polyunsaturated fatty acids (PUFAs) to form 9S- and 11S-hydroperoxy fatty acids, which were reduced to 9S- and 11S-hydroxy fatty acids (HFAs) by cysteine, respectively, and it catalyzed again oxygenation at the n-6 position of HFAs to form 9S,15S- and 11S,17S-DiHFAs, respectively. The regioselective residues of 9S-LOX were determined as lle395 and Val569 based on the amino acid alignment and homology models. The regioselectivity of the I395F variant was changed from the n-12 position on C20 PUFA to the n-6 position to form 15S-HFAs. This may be due to the reduction of the substrate-binding pocket by replacing the smaller Ile with a larger Phe. The V569W variant had a significantly lower second­oxygenating activity compared to wild-type 9S-LOX because the insertion of the hydroxyl group of the first­oxygenating products at the active site was seemed to be hindered by substituting a larger Trp for a smaller Val. The compounds, 11S-hydroxydocosapentaenoic acid, 9S,15S-dihydroxyeicosatetraenoic acid, 9S,15S-dihydroxyeicosapentaenoic acid, 11S,17S-hydroxydocosapentaenoic acid, and 11S,17S-dihydroxydocosahexaenoic acid, were newly identified by polarimeter, LC-MS/MS, and NMR. 11S,17S-DiHFAs as SPM isomers biosynthesized from C22 PUFAs showed anti-inflammatory activities in mouse and human cells. Our study contributes may stimulate physiological studies by providing new LMs.